HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health OTC Drugs Safety

France Wants To Move Paracetamol, Ibuprofen And Aspirin Behind The Counter

  • News

Executive Summary

France's medicines agency wants to restrict sales of OTC drugs containing paracetamol, ibuprofen and aspirin to behind the pharmacy counter due to safety concerns.

You may also be interested in...



France Moving Paracetamol and NSAIDs Behind Pharmacy Counter From January

Fears over patient safety will see common OTC drugs including paracetamol moved behind the counter in France from January 2020.

Sore Throat Drugs Heading Behind The Counter In France Over Safety Fears

France's drugs agency wants to restrict sales of OTC sore throat treatments marketed by Sanofi and others to behind the pharmacy counter due to fears of potential adverse events.

Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3

Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.

Table

View full table

Related Content

HBW Insight
HBW Insight
HBW Insight
HBW Insight
HBW Insight
HBW Insight
HBW Insight

Topics

Related Companies

Tags:
Health OTC Drugs Safety
UsernamePublicRestriction

Register

RS149278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By